OraSure Technologies Competitors

Align Technology (NASDAQ:ALGN) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.2% of Align Technology shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Align Technology and OraSure Technologies, as provided by MarketBeat.com.

Align Technology currently has a consensus target price of $501.3333, suggesting a potential downside of 15.03%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than Align Technology.

Profitability

This table compares Align Technology and OraSure Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Align Technology and OraSure Technologies' gross revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

Align Technology beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for West Pharmaceutical Services and OraSure Technologies, as provided by MarketBeat.com.

West Pharmaceutical Services currently has a consensus target price of $310.00, suggesting a potential upside of 2.51%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' higher possible upside, analysts plainly believe OraSure Technologies is more favorable than West Pharmaceutical Services.

Profitability

This table compares West Pharmaceutical Services and OraSure Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares West Pharmaceutical Services and OraSure Technologies' gross revenue, earnings per share and valuation.

West Pharmaceutical Services has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

West Pharmaceutical Services beats OraSure Technologies on 9 of the 13 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for The Cooper Companies and OraSure Technologies, as provided by MarketBeat.com.

The Cooper Companies currently has a consensus target price of $384.25, suggesting a potential downside of 1.22%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than The Cooper Companies.

Profitability

This table compares The Cooper Companies and OraSure Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares The Cooper Companies and OraSure Technologies' gross revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than OraSure Technologies. The Cooper Companies is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

The Cooper Companies beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Risk and Volatility

DENTSPLY SIRONA has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Earnings and Valuation

This table compares DENTSPLY SIRONA and OraSure Technologies' gross revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than OraSure Technologies. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and OraSure Technologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for DENTSPLY SIRONA and OraSure Technologies, as provided by MarketBeat.com.

DENTSPLY SIRONA currently has a consensus target price of $55.3333, suggesting a potential downside of 14.77%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than DENTSPLY SIRONA.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

DENTSPLY SIRONA beats OraSure Technologies on 8 of the 14 factors compared between the two stocks.

OraSure Technologies (NASDAQ:OSUR) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

OraSure Technologies has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Earnings & Valuation

This table compares OraSure Technologies and Haemonetics' gross revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than OraSure Technologies. Haemonetics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OraSure Technologies and Haemonetics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OraSure Technologies and Haemonetics, as reported by MarketBeat.com.

OraSure Technologies presently has a consensus price target of $17.50, suggesting a potential upside of 69.25%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.33%. Given OraSure Technologies' higher possible upside, research analysts plainly believe OraSure Technologies is more favorable than Haemonetics.

Insider and Institutional Ownership

98.1% of OraSure Technologies shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 1.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Haemonetics beats OraSure Technologies on 10 of the 13 factors compared between the two stocks.

OraSure Technologies (NASDAQ:OSUR) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

OraSure Technologies has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares OraSure Technologies and Quidel's gross revenue, earnings per share (EPS) and valuation.

Quidel has higher revenue and earnings than OraSure Technologies. Quidel is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OraSure Technologies and Quidel's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OraSure Technologies and Quidel, as reported by MarketBeat.com.

OraSure Technologies presently has a consensus price target of $17.50, suggesting a potential upside of 69.25%. Quidel has a consensus price target of $262.75, suggesting a potential upside of 104.41%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than OraSure Technologies.

Insider and Institutional Ownership

98.1% of OraSure Technologies shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 1.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 14.1% of Quidel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quidel beats OraSure Technologies on 11 of the 14 factors compared between the two stocks.